Remove Antibody Remove Licensing Remove Vaccine
article thumbnail

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech

pharmaphorum

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. One of the primary advantages of this approach is that the oral vaccine capsules are stable at room temperature, which means they do not require cold chain storage.

Licensing 119
article thumbnail

Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells

BioPharma Reporter

Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.

Antibody 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Syncromune and Eucure enter antibody licence deal

Pharmaceutical Technology

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Syncromune president and CEO Eamonn Hobbs said: “We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen.

Antibody 130
article thumbnail

South Korea authorises Novavax Covid-19 vaccine as booster dose

Pharmaceutical Technology

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

article thumbnail

Evaxion and ExpreS²ion partner to develop new CMV vaccine

Pharmaceutical Technology

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

article thumbnail

US FDA grants EUA to InflaRx’s Covid-19 treatment

Pharmaceutical Technology

It is a first-in-class monoclonal anti-human complement factor C5a antibody. Despite the availability of vaccines and other treatments for earlier disease stages of Covid-19, many patients are still developing viral sepsis and are progressing to critical status, which often requires invasive mechanical ventilation.

Licensing 246